Seelos Therapeutics Announces the Selection of SLS-002 for Inclusion in the U.S. Department of Defense's Adaptive Platform Trial to Evaluate Potential Treatments for Post-Traumatic Stress Disorder Psychedelics Investing
Eminent Healthcare Leader Appointed as Independent Non-Executive Chairman for Emyria Ltd Cannabis Investing News
Compass Pathways initiates UK component of global phase 3 study of psilocybin treatment in treatment-resistant depression and launches new research center Psychedelics Investing
Goodness Growth Holdings to Release Third Quarter 2023 Results on November 14, 2023 Psychedelics Investing
COMPASS Pathways Announces Third Quarter 2023 Financial Results and Business Highlights Psychedelics Investing
